Dalbavancin

Structural formula
Structure of dalbavancin B 0
General
Non-proprietary name	Dalbavancin
Molecular formula	C 88 H 100 Cl 2 N 10 O 28 (Dalbavancin B 0 )
External identifiers / databases
CAS number 171500-79-1 PubChem 16134627 DrugBank DB06219 Wikidata Q5210237
Drug information
ATC code	J01 XA04
properties
Molar mass	1816.71 g mol −1 (dalbavancin B0)
safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed GHS hazard labeling no classification available
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Dalbavancin (trade name Xydalba ; pharmaceutical company Allergan Pharmaceuticals International Ltd; manufacturer Almac Pharma Services ) is an antibiotic from the group of glycopeptide antibiotics used as a drug in the treatment of acute bacterial skin and soft tissue infections in adults.

Clinical information

application areas

Dalbavancin is an antibiotic used in adults to treat acute bacterial infections of the skin and structures of the skin (tissue under the skin) such as cellulitis (inflammation of the subcutaneous tissue), skin abscesses and wound infections.

Type and duration of application

Dalbavancin is administered intravenously as a solution for infusion as a single dose or two doses one week apart.

unwanted effects

The most important side effects are development of resistance , pseudomembranous colitis and hypersensitivity reactions .

The most common side effects (may affect 1 to 3 in 100 people) are nausea , diarrhea and headache .

Pharmacological properties

Mechanism of action

Dalbavancin is a bactericidal lipoglycopeptide antibiotic. It works by killing certain bacteria that can cause serious infections. It kills these bacteria by disrupting the formation of the bacterial cell walls.

Manufacture and composition

Dalbavancin is a semi-synthetic cyclic lipoglycopeptide. It is produced by fermentation with Nonomuraea bacteria and subsequent chemical modification. Dalbavancin is a mixture of five closely related homologues from two structural families, Dalbavancin A and Dalbavancin B. They differ mainly in their different fatty acid side chains and a methyl group at the amino terminus .

Dalbavancin homologs

Homologous	Fatty acid side chain of the N -acylaminoglucuronic acid unit R 1	Substituent at the amino terminus R 2
A 0	-CH (CH 3 ) 2	-H
A 1	-CH 2 CH 2 CH 3	-H
B 0	-CH 2 CH (CH 3 ) 2	-H
B 1	-CH 2 CH 2 CH 2 CH 3	-H
B 2	-CH 2 CH (CH 3 ) 2	-CH 3

Other Information

On February 19, 2015, the European Commission granted marketing authorization for Xydalba throughout the European Union. Given the need for new antibiotics against multi-resistant bacteria, the European Medicines Agency concluded that dalbavancin could be a valuable alternative treatment option. The safety profile is similar to that of other antibiotics of the glycopeptide class. Side effects on hearing and kidney function typical of glycopeptides were not observed with the proposed therapy regimens in clinical trials.

Trade names

• Monopreparation : Xydalba

Web links

• Public Assessment Report (EPAR) of the European Medicines Agency (EMA) for: Dalbavancin

Individual evidence

1. ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
2. ↑ ^{a b c} Summary of the EPAR for the public: Dalbavancin. (PDF; 76 kB) EMA , accessed on January 25, 2017 . 
3. ^ Summary of the risk management plan (RMP) for Xydalba (dalbavacin). (PDF; 94 kB) EMA , accessed on January 25, 2017 (English). 
4. ↑ Appendix I: Summary of Product Characteristics. (PDF; 257 kB) EMA , accessed on January 25, 2017 . 
5. ↑ Assessment report: Xydalba. (PDF; 2.6 MB) EMA , accessed on January 25, 2017 (English). 

This article is about a health issue. It is not used for self-diagnosis and does not replace a diagnosis by a doctor. Please note the information on health issues !